Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Share-based Compensation (2018 - 2025)

UroGen Pharma (URGN) has disclosed Share-based Compensation for 8 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 5.24% year-over-year to $3.1 million, compared with a TTM value of $12.0 million through Dec 2025, down 8.77%, and an annual FY2025 reading of $12.0 million, down 8.77% over the prior year.
  • Share-based Compensation was $3.1 million for Q4 2025 at UroGen Pharma, up from $3.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.2 million in Q1 2021 and bottomed at $2.2 million in Q2 2023.
  • Average Share-based Compensation over 5 years is $3.4 million, with a median of $3.0 million recorded in 2022.
  • The sharpest move saw Share-based Compensation crashed 55.8% in 2022, then soared 60.22% in 2024.
  • Year by year, Share-based Compensation stood at $5.4 million in 2021, then crashed by 55.8% to $2.4 million in 2022, then increased by 10.26% to $2.6 million in 2023, then increased by 26.5% to $3.3 million in 2024, then decreased by 5.24% to $3.1 million in 2025.
  • Business Quant data shows Share-based Compensation for URGN at $3.1 million in Q4 2025, $3.0 million in Q3 2025, and $2.7 million in Q2 2025.